Bimekizumab Lowers Uveitis Rates in Axial Spondyloarthritis

In patients with axial spondyloarthritis, bimekizumab — a dual interleukin-17A/F inhibitor — showed a lower incidence rate of uveitis, suggesting protective effects against acute anterior uveitis.
Medscape Medical News

source https://www.medscape.com/viewarticle/bimekizumab-lowers-uveitis-rates-axial-spondyloarthritis-2024a1000fli?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?